argenx Meets Primary Endpoint in Phase 3 ALKIVIA Trial for Autoimmune Myositis
ARGX Argen X SE ADR
$851.29 -0.66%
View chart & analysis → - 1argenx (ARGX) announces VYVGART Hytrulo met the primary endpoint in the Phase 3 ALKIVIA trial in adult patients with autoimmune myositis
- 2Mean TIS at 52 weeks was 47.95 vs 32.56 for placebo, a 15.4-point advantage (p=0.0011) in the integrated primary analysis of IMNM and DM
- 3IMNM, a subtype with no approved therapy, showed first significant Phase 3 improvement; DM showed clinically meaningful improvement but missed statistical significance at p=0.1093
This 3-line summary is compiled from the report below.
InvestorsHub +1 View original ↗
오늘의 AI 픽 5종목, 무료로 전부 공개합니다숨기는 것 없이 — 지난 픽의 성적표(S&P500 대비)까지 그대로 보여드립니다